Form 8-K - Current report:
SEC Accession No. 0001171843-25-003661
Filing Date
2025-06-04
Accepted
2025-06-04 07:00:11
Documents
20
Period of Report
2025-06-04
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_060425.htm   iXBRL 8-K 27148
2 PRESS RELEASE exh_991.htm EX-99.1 13613
7 GRAPHIC fig1.jpg GRAPHIC 23191
8 GRAPHIC fig2.jpg GRAPHIC 18710
9 GRAPHIC fig3.jpg GRAPHIC 16661
10 GRAPHIC exh991fig1.jpg GRAPHIC 34311
11 GRAPHIC exh991fig2.jpg GRAPHIC 26083
12 GRAPHIC exh991fig3.jpg GRAPHIC 16875
  Complete submission text file 0001171843-25-003661.txt   491128

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3003
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25598
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
22 EXTRACTED XBRL INSTANCE DOCUMENT f8k_060425_htm.xml XML 3344
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 251021870
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)